<SEC-DOCUMENT>0001075880-13-000004.txt : 20130205
<SEC-HEADER>0001075880-13-000004.hdr.sgml : 20130205
<ACCEPTANCE-DATETIME>20130204182016
ACCESSION NUMBER:		0001075880-13-000004
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20130204
FILED AS OF DATE:		20130205
DATE AS OF CHANGE:		20130204

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		13571445

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		1 - 7 WATERLOO ROAD
		CITY:			NORTH RYDE NSW
		STATE:			C3
		ZIP:			2113
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		1 - 7 WATERLOO ROAD
		CITY:			NORTH RYDE NSW
		STATE:			C3
		ZIP:			2113
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6kshareissue.htm
<DESCRIPTION>SHARES ISSUED TO TRIAXIAL SHAREHOLDERS
<TEXT>
<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>Converted by EDGARwiz</TITLE>
</HEAD>
<BODY style="margin-top:0;font-family:Times New Roman; font-size:10pt; color:#000000">
<DIV style="width:649.733px"><P style="margin-top:41.933px; margin-bottom:0px; text-indent:247.733px; font-size:9.95pt"><B>UNITED STATES</B></P>
<P style="margin-top:2.733px; margin-bottom:0px; text-indent:157.267px; font-size:9.95pt"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>
<P style="margin-top:2.733px; margin-bottom:0px; text-indent:231.733px; font-size:9.95pt"><B>Washington, D.C. 20549</B></P>
<P style="margin-top:18.4px; margin-bottom:0px; text-indent:261.133px; font-size:14pt"><B>Form 6-K</B></P>
<P style="margin-top:17.6px; margin-bottom:0px; text-indent:11.533px; font-size:11.5pt"><B>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16</B></P>
<P style="margin-top:4px; margin-bottom:0px; text-indent:112.8px; font-size:11.5pt"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>
<P style="margin-top:16.867px; margin-bottom:0px; font-size:9.95pt">For the month of February, 2013.</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-size:9.95pt">Commission File Number ________________</P>
<P style="margin-top:36.2px; margin-bottom:0px; text-indent:202.733px; font-size:20pt"><B>Novogen Limited</B></P>
<P style="margin-top:1px; margin-bottom:0px; text-indent:177px; font-size:9.95pt">(Translation of registrant<font style='font-family:Arial Unicode MS,Times New Roman'>&#8217;</font>s name into English)</P>
<P style="margin-top:20.867px; margin-bottom:0px; text-indent:150.867px; font-size:12pt">140 Wicks Road, North Ryde, NSW, Australia</P>
<P style="margin-top:2.467px; margin-bottom:0px; text-indent:197.667px; font-size:9.95pt">(Address of principal executive office)</P>
<P style="margin-top:20.467px; margin-bottom:0px; font-size:9.95pt">Indicate by check mark whether the registrant files or will file<FONT style="font-size:5.6pt"> &nbsp;</FONT>annual reports under cover of Form</P>
<P style="margin-top:4.8px; margin-bottom:0px; font-size:9.95pt">20-F or Form 40-F.</P>
<P style="margin-top:2.067px; margin-bottom:0px; font-size:9.95pt">Form 20-F<FONT style="font-family:Wingdings"><font style='font-family:Arial Unicode MS,Times New Roman'>&#61472;</font></FONT><FONT style="font-family:Wingdings; font-size:5.8pt"> &nbsp;</FONT><FONT style="font-family:Wingdings"><font style='font-family:Arial Unicode MS,Times New Roman'>&#61472;</font></FONT><FONT style="font-family:Wingdings 2"><font style='font-family:Arial Unicode MS,Times New Roman'>&#61472;</font></FONT>Form 40-F<FONT style="font-family:Wingdings"><font style='font-family:Arial Unicode MS,Times New Roman'>&#61472;</font></FONT></P>
<P style="margin-top:5.133px; margin-bottom:0px; font-family:Wingdings 2; font-size:5pt">&nbsp;<FONT style="font-size:9.95pt"><font style='font-family:Arial Unicode MS,Times New Roman'>&#61472;</font></FONT></P>
<P style="margin-top:2.533px; margin-bottom:0px; font-size:9.95pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T</P>
<P style="margin-top:2.533px; margin-bottom:0px; font-size:9.95pt">Rule 101(b)(1):</P>
<P style="margin-top:18.533px; margin-bottom:0px; font-size:9.95pt"><B>Note</B>: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to</P>
<P style="margin-top:2.533px; margin-bottom:0px; font-size:9.95pt">provide an attached annual report to security holders.</P>
<P style="margin-top:18.4px; margin-bottom:0px; font-size:9.95pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T</P>
<P style="margin-top:2.533px; margin-bottom:0px; font-size:9.95pt">Rule 101(b)(7):</P>
<P style="margin-top:18.533px; margin-bottom:0px; font-size:9.95pt"><B>Note</B>: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-size:9.95pt">a report or other document that the registrant foreign private issuer must furnish and make public under the laws</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-size:9.95pt">of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant<font style='font-family:Arial Unicode MS,Times New Roman'>&#8217;</font>s <font style='font-family:Arial Unicode MS,Times New Roman'>&#8220;</font>home</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-size:9.95pt">country<font style='font-family:Arial Unicode MS,Times New Roman'>&#8221;</font>), or under the rules of the home country exchange on which the registrant<font style='font-family:Arial Unicode MS,Times New Roman'>&#8217;</font>s securities are traded, as</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-size:9.95pt">long as the report or other document is not a press release, is not required to be and has not been distributed to</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-size:9.95pt">the registrant<font style='font-family:Arial Unicode MS,Times New Roman'>&#8217;</font>s security holders, and, if discussing a material event, has already been the subject of a Form 6-K</P>
<P style="margin-top:2.533px; margin-bottom:0px; font-size:9.95pt">submission or other Commission filing on EDGAR.</P>
<P style="margin-top:18.533px; margin-bottom:0px; font-size:9.95pt">Indicate by check mark if the registrant by furnishing the information<FONT style="font-size:5.5pt"> &nbsp;</FONT>contained in this form is also thereby</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-size:9.95pt">furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of</P>
<P style=margin-top:2.533px;margin-bottom:-1pt;font-size:1pt /><P style="margin-top:0px; margin-bottom:-2px; width:79.533px; font-size:9.95pt; float:left">1934. &nbsp;Yes</P>
<P style="margin:0px; text-indent:-2px; font-family:Wingdings 2; font-size:9.95pt"><font style='font-family:Arial Unicode MS,Times New Roman'>&#61472;</font><FONT style="font-family:Times New Roman">No</FONT></P>
<P style="margin-top:17.733px; margin-bottom:0px; font-size:9.95pt; clear:left">If <font style='font-family:Arial Unicode MS,Times New Roman'>&#8220;</font>yes<font style='font-family:Arial Unicode MS,Times New Roman'>&#8221;</font> is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b)</P>
<P style="margin-top:19.2px; margin-bottom:0px; text-indent:257.667px; font-size:9.95pt"><B>SIGNATURES</B></P>
<P style="margin-top:2.733px; margin-bottom:0px; font-size:9.95pt"><B>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this</B></P>
<P style="margin-top:2.267px; margin-bottom:0px; font-size:9.95pt"><B>report to be signed on its behalf</B> by the undersigned, thereunto duly authorized.</P>
<P style="margin-top:18.4px; margin-bottom:0px; font-size:9.95pt"><B>Novogen Limited</B> (Registrant)</P>
<P style="margin-top:17.733px; margin-bottom:0px; font-size:9.95pt">(Signature) *</P>
<P style="margin-top:2.067px; margin-bottom:0px; font-size:9.95pt">Andrew Bursill</P>
<P style="margin-top:17.267px; margin-bottom:0px; font-size:9.95pt">Date 4 February 2013</P>
<P style="margin-top:17.2px; margin-bottom:0px; font-size:9pt">* Print the name and title under the signature of the signing officer.</P>
<P style="margin-top:17.2px; margin-bottom:0px"><BR>
<BR></P>
</DIV><DIV style="width:625.267px"><P style="margin-top:104.333px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:11pt; page-break-before:always"><B>5 February 2013</B></P>
<P style="margin-top:19.6px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:11pt"><B>ASX RELEASE</B></P>
<P style="margin-top:29.2px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:15.95pt"><B>Allocation of</B><FONT style="font-size:9.15pt"><B> &nbsp;</B></FONT><B>Novogen Shares to</B><FONT style="font-size:9.05pt"><B> &nbsp;</B></FONT><B>Triaxial</B><FONT style="font-size:8.95pt"><B> &nbsp;</B></FONT><B>Pharmaceutical</B></P>
<P style="margin-top:3.8px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:15.95pt"><B>Pty Ltd Shareholders</B></P>
<P style="margin-top:27.2px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">On<FONT style="font-size:8.35pt"> &nbsp;</FONT>7<FONT style="font-size:8.3pt"> &nbsp;</FONT>December<FONT style="font-size:8.3pt"> &nbsp;</FONT>2012,<FONT style="font-size:8.8pt"> &nbsp;</FONT>Novogen<FONT style="font-size:8.5pt"> &nbsp;</FONT>Ltd<FONT style="font-size:8.3pt"> &nbsp;</FONT>(<font style='font-family:Arial Unicode MS,Times New Roman'>&#8216;</font>Novogen<font style='font-family:Arial Unicode MS,Times New Roman'>&#8217;</font>)<FONT style="font-size:8.3pt"> &nbsp;</FONT>announced<FONT style="font-size:8.25pt"> &nbsp;</FONT>that<FONT style="font-size:8.5pt"> &nbsp;</FONT>it<FONT style="font-size:8.5pt"> &nbsp;</FONT>had<FONT style="font-size:8.25pt"> &nbsp;</FONT>acquired</P>
<P style="margin-top:2.867px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">all shares in the Australian biotechnology company,<FONT style="font-size:6.6pt"> &nbsp;</FONT>Triaxial Pharmaceuticals Pty</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">Ltd (ACN 139 717 543) (<font style='font-family:Arial Unicode MS,Times New Roman'>&#8216;</font>Triaxial<font style='font-family:Arial Unicode MS,Times New Roman'>&#8217;</font>).</P>
<P style="margin-top:21.467px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">The<FONT style="font-size:10.5pt"> &nbsp;&nbsp;</FONT>purpose<FONT style="font-size:10.5pt"> &nbsp;&nbsp;</FONT>of<FONT style="font-size:10.45pt"> &nbsp;&nbsp;</FONT>the<FONT style="font-size:10.55pt"> &nbsp;&nbsp;</FONT>acquisition<FONT style="font-size:10.55pt"> &nbsp;&nbsp;</FONT>was<FONT style="font-size:10.55pt"> &nbsp;&nbsp;</FONT>to<FONT style="font-size:10.5pt"> &nbsp;&nbsp;</FONT>provide<FONT style="font-size:10.55pt"> &nbsp;&nbsp;</FONT>the<FONT style="font-size:10.55pt"> &nbsp;&nbsp;</FONT>Company<FONT style="font-size:10.45pt"> &nbsp;&nbsp;</FONT>with<FONT style="font-size:10.45pt"> &nbsp;&nbsp;</FONT>a<FONT style="font-size:10.55pt"> &nbsp;&nbsp;</FONT>new</P>
<P style="margin-top:2.933px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">technology &nbsp;platform &nbsp;that &nbsp;Triaxial &nbsp;believes &nbsp;offers &nbsp;the &nbsp;opportunity &nbsp;for &nbsp;the &nbsp;first</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">time<FONT style="font-size:7.3pt"> &nbsp;</FONT>to<FONT style="font-size:7.35pt"> &nbsp;</FONT>customize<FONT style="font-size:7.35pt"> &nbsp;</FONT>the<FONT style="font-size:7.35pt"> &nbsp;</FONT>design<FONT style="font-size:7.35pt"> &nbsp;</FONT>of<FONT style="font-size:7.2pt"> &nbsp;</FONT>anti-cancer<FONT style="font-size:7.25pt"> &nbsp;</FONT>drugs<FONT style="font-size:7.3pt"> &nbsp;</FONT>and<FONT style="font-size:7.2pt"> &nbsp;</FONT>to<FONT style="font-size:7.35pt"> &nbsp;</FONT>be<FONT style="font-size:7.35pt"> &nbsp;</FONT>able<FONT style="font-size:7.35pt"> &nbsp;</FONT>to<FONT style="font-size:7.35pt"> &nbsp;</FONT>manufacture</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">those drugs in a cost-effective and practical way.</P>
<P style="margin-top:21.6px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">The acquisition was funded through a loan to the value of $1,885,000 in the form</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">of<FONT style="font-size:9.1pt"> &nbsp;</FONT>a<FONT style="font-size:9.3pt"> &nbsp;</FONT>Convertible<FONT style="font-size:9.25pt"> &nbsp;</FONT>Note<FONT style="font-size:9.25pt"> &nbsp;</FONT>from<FONT style="font-size:9.15pt"> &nbsp;</FONT>Triaxial<FONT style="font-size:9.6pt"> &nbsp;</FONT>Shareholders<FONT style="font-size:9.35pt"> &nbsp;</FONT>to<FONT style="font-size:9.25pt"> &nbsp;</FONT>Novogen<FONT style="font-size:9.4pt"> &nbsp;</FONT>to<FONT style="font-size:9.25pt"> &nbsp;</FONT>be<FONT style="font-size:9.3pt"> &nbsp;</FONT>repaid<FONT style="font-size:9.1pt"> &nbsp;</FONT>in<FONT style="font-size:9.3pt"> &nbsp;</FONT>4</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">tranches as follows:</P>
<P style="margin-top:21.467px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">Tranche 1 on completion of the acquisition;</P>
<P style="margin-top:2.867px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">Tranche 2 on completion of a Phase I trial;</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">Tranche 3 on receipt of an IND from the FDA;</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">Tranche 4 on completion of a Phase II trial.</P>
<P style="margin-top:21.6px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">Triaxial &nbsp;shareholders &nbsp;are &nbsp;entitled &nbsp;to &nbsp;convert &nbsp;tranche &nbsp;payments &nbsp;into &nbsp;ordinary</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">shares<FONT style="font-size:6.8pt"> &nbsp;</FONT>in<FONT style="font-size:6.85pt"> &nbsp;</FONT>Novogen<FONT style="font-size:6.85pt"> &nbsp;</FONT>Limited,<FONT style="font-size:6.95pt"> &nbsp;</FONT>which<FONT style="font-size:6.7pt"> &nbsp;</FONT>it<FONT style="font-size:6.85pt"> &nbsp;</FONT>now<FONT style="font-size:6.7pt"> &nbsp;</FONT>proposes<FONT style="font-size:7.05pt"> &nbsp;</FONT>to<FONT style="font-size:6.8pt"> &nbsp;</FONT>do<FONT style="font-size:6.75pt"> &nbsp;</FONT>with<FONT style="font-size:6.7pt"> &nbsp;</FONT>the<FONT style="font-size:6.8pt"> &nbsp;</FONT>first<FONT style="font-size:6.75pt"> &nbsp;</FONT>tranche<FONT style="font-size:6.8pt"> &nbsp;</FONT>in</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">the<FONT style="font-size:8.75pt"> &nbsp;</FONT>form<FONT style="font-size:8.6pt"> &nbsp;</FONT>of<FONT style="font-size:8.55pt"> &nbsp;</FONT>15,400,000<FONT style="font-size:8.8pt"> &nbsp;</FONT>ordinary<FONT style="font-size:8.5pt"> &nbsp;</FONT>Novogen<FONT style="font-size:8.75pt"> &nbsp;</FONT>shares.<FONT style="font-size:8.85pt"> &nbsp;</FONT>Under<FONT style="font-size:8.6pt"> &nbsp;</FONT>Listing<FONT style="font-size:8.6pt"> &nbsp;</FONT>Rule<FONT style="font-size:8.7pt"> &nbsp;</FONT>7.1<FONT style="font-size:8.55pt"> &nbsp;</FONT>which</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">allows<FONT style="font-size:9.05pt"> &nbsp;&nbsp;</FONT>a<FONT style="font-size:9.1pt"> &nbsp;&nbsp;</FONT>maximum<FONT style="font-size:9pt"> &nbsp;&nbsp;</FONT>issuance<FONT style="font-size:9.1pt"> &nbsp;&nbsp;</FONT>of<FONT style="font-size:9pt"> &nbsp;&nbsp;</FONT>15%<FONT style="font-size:9.2pt"> &nbsp;&nbsp;</FONT>of<FONT style="font-size:9pt"> &nbsp;&nbsp;</FONT>issued<FONT style="font-size:9pt"> &nbsp;&nbsp;</FONT>capital<FONT style="font-size:9.05pt"> &nbsp;&nbsp;</FONT>within<FONT style="font-size:9.1pt"> &nbsp;&nbsp;</FONT>any<FONT style="font-size:9pt"> &nbsp;&nbsp;</FONT>12-month</P>
<P style="margin-top:2.867px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">period,<FONT style="font-size:9.5pt"> &nbsp;&nbsp;</FONT>13,600,000<FONT style="font-size:9.35pt"> &nbsp;&nbsp;</FONT>shares<FONT style="font-size:9.4pt"> &nbsp;&nbsp;</FONT>are<FONT style="font-size:9.4pt"> &nbsp;&nbsp;</FONT>to<FONT style="font-size:9.45pt"> &nbsp;&nbsp;</FONT>be<FONT style="font-size:9.25pt"> &nbsp;&nbsp;</FONT>issued<FONT style="font-size:9.2pt"> &nbsp;&nbsp;</FONT>immediately<FONT style="font-size:9.3pt"> &nbsp;&nbsp;</FONT>and<FONT style="font-size:9.3pt"> &nbsp;&nbsp;</FONT>the<FONT style="font-size:9.25pt"> &nbsp;&nbsp;</FONT>remaining</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">1,800,000 shares in April 2013, upon shareholder approval.</P>
<P style="margin-top:21.467px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">The<FONT style="font-size:8.7pt"> &nbsp;</FONT>company<FONT style="font-size:8.55pt"> &nbsp;</FONT>intends<FONT style="font-size:8.7pt"> &nbsp;</FONT>to<FONT style="font-size:8.65pt"> &nbsp;</FONT>call<FONT style="font-size:8.65pt"> &nbsp;</FONT>an<FONT style="font-size:8.75pt"> &nbsp;</FONT>Extraordinary<FONT style="font-size:8.75pt"> &nbsp;</FONT>General<FONT style="font-size:8.7pt"> &nbsp;</FONT>Meeting<FONT style="font-size:8.55pt"> &nbsp;</FONT>of<FONT style="font-size:8.55pt"> &nbsp;</FONT>shareholders</P>
<P style="margin-top:2.867px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">within<FONT style="font-size:7.65pt"> &nbsp;</FONT>the<FONT style="font-size:7.65pt"> &nbsp;</FONT>next<FONT style="font-size:7.55pt"> &nbsp;</FONT>3<FONT style="font-size:7.45pt"> &nbsp;</FONT>months<FONT style="font-size:7.8pt"> &nbsp;</FONT>to<FONT style="font-size:7.6pt"> &nbsp;</FONT>ratify,<FONT style="font-size:7.7pt"> &nbsp;</FONT>among<FONT style="font-size:7.5pt"> &nbsp;</FONT>other<FONT style="font-size:7.5pt"> &nbsp;</FONT>things,<FONT style="font-size:7.95pt"> &nbsp;</FONT>the<FONT style="font-size:7.65pt"> &nbsp;</FONT>terms<FONT style="font-size:7.55pt"> &nbsp;</FONT>of<FONT style="font-size:7.5pt"> &nbsp;</FONT>the<FONT style="font-size:7.6pt"> &nbsp;</FONT>Triaxial</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">acquisition.<FONT style="font-size:10.25pt"> &nbsp;</FONT>Further<FONT style="font-size:10pt"> &nbsp;</FONT>details<FONT style="font-size:10.05pt"> &nbsp;</FONT>on<FONT style="font-size:10.05pt"> &nbsp;</FONT>this<FONT style="font-size:10.1pt"> &nbsp;</FONT>meeting<FONT style="font-size:10pt"> &nbsp;</FONT>will<FONT style="font-size:10.05pt"> &nbsp;</FONT>be<FONT style="font-size:10.1pt"> &nbsp;</FONT>forwarded<FONT style="font-size:9.95pt"> &nbsp;</FONT>to<FONT style="font-size:10.3pt"> &nbsp;</FONT>shareholders</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">shortly.</P>
<P style="margin-top:40.333px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt"><B>About Novogen</B></P>
<P style="margin-top:4.933px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">Novogen<FONT style="font-size:9.05pt"> &nbsp;</FONT>Ltd<FONT style="font-size:8.85pt"> &nbsp;</FONT>is<FONT style="font-size:9pt"> &nbsp;</FONT>a<FONT style="font-size:8.75pt"> &nbsp;</FONT>public<FONT style="font-size:8.9pt"> &nbsp;</FONT>Australian<FONT style="font-size:9.05pt"> &nbsp;</FONT>biotechnology<FONT style="font-size:8.85pt"> &nbsp;</FONT>company<FONT style="font-size:8.85pt"> &nbsp;</FONT>whose<FONT style="font-size:9pt"> &nbsp;</FONT>shares<FONT style="font-size:9pt"> &nbsp;</FONT>trade</P>
<P style="margin-top:4.933px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">on &nbsp;both &nbsp;the &nbsp;Australian &nbsp;Stock &nbsp;Exchange &nbsp;(symbol &nbsp;<font style='font-family:Arial Unicode MS,Times New Roman'>&#8216;</font>NRT<font style='font-family:Arial Unicode MS,Times New Roman'>&#8217;</font>) &nbsp;and &nbsp;NASDAQ &nbsp;(symbol</P>
<P style="margin-top:4.933px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt"><font style='font-family:Arial Unicode MS,Times New Roman'>&#8216;</font>NVGN<font style='font-family:Arial Unicode MS,Times New Roman'>&#8217;</font>).<FONT style="font-size:10pt"> &nbsp;&nbsp;&nbsp;&nbsp;</FONT>The &nbsp;Company &nbsp;is &nbsp;based &nbsp;in<FONT style="font-size:8.4pt"> &nbsp;&nbsp;</FONT>Sydney,<FONT style="font-size:8.75pt"> &nbsp;&nbsp;</FONT>Australia &nbsp;and &nbsp;is &nbsp;focused &nbsp;on &nbsp;the</P>
<P style="margin-top:5.133px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">development<FONT style="font-size:8.45pt"> &nbsp;</FONT>of<FONT style="font-size:8.3pt"> &nbsp;</FONT>a<FONT style="font-size:8.45pt"> &nbsp;</FONT>family<FONT style="font-size:8.3pt"> &nbsp;</FONT>of<FONT style="font-size:8.3pt"> &nbsp;</FONT>novel<FONT style="font-size:8.35pt"> &nbsp;</FONT>anti-cancer<FONT style="font-size:8.05pt"> &nbsp;</FONT>drugs<FONT style="font-size:8.4pt"> &nbsp;</FONT>based<FONT style="font-size:8.25pt"> &nbsp;</FONT>on<FONT style="font-size:8.45pt"> &nbsp;</FONT>super-benzopyran</P>
<P style="margin-top:4.933px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">and <font style='font-family:Arial Unicode MS,Times New Roman'>&#8216;</font>stealth<font style='font-family:Arial Unicode MS,Times New Roman'>&#8217;</font> drug technologies. The Company<font style='font-family:Arial Unicode MS,Times New Roman'>&#8217;</font>s inaugural drug candidate is CS-6.</P>
<P style="margin-top:27.667px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt"><B>About CS-6</B></P>
<P style="margin-top:27.667px; margin-bottom:0px"><BR>
<BR></P>
<P style="margin-top:72.933px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt; page-break-before:always">CS-6<FONT style="font-size:9.4pt"> &nbsp;</FONT>belongs<FONT style="font-size:9.45pt"> &nbsp;</FONT>to<FONT style="font-size:9.5pt"> &nbsp;</FONT>a<FONT style="font-size:9.55pt"> &nbsp;</FONT>new<FONT style="font-size:9.4pt"> &nbsp;</FONT>class<FONT style="font-size:9.5pt"> &nbsp;</FONT>of<FONT style="font-size:9.4pt"> &nbsp;</FONT>drug<FONT style="font-size:9.4pt"> &nbsp;</FONT>candidates<FONT style="font-size:9.5pt"> &nbsp;</FONT>known<FONT style="font-size:9.45pt"> &nbsp;</FONT>(structurally)<FONT style="font-size:9.7pt"> &nbsp;</FONT>as<FONT style="font-size:9.55pt"> &nbsp;</FONT>super-</P>
<P style="margin-top:4.933px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">benzopyrans<FONT style="font-size:7.15pt"> &nbsp;</FONT>displaying<FONT style="font-size:6.95pt"> &nbsp;</FONT>potent<FONT style="font-size:6.85pt"> &nbsp;</FONT>anti-cancer<FONT style="font-size:7pt"> &nbsp;</FONT>activity<FONT style="font-size:7.1pt"> &nbsp;</FONT>and<FONT style="font-size:6.9pt"> &nbsp;</FONT>demonstrating<FONT style="font-size:7pt"> &nbsp;</FONT>increased</P>
<P style="margin-top:5px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">bio-availability<FONT style="font-size:8.6pt"> &nbsp;&nbsp;</FONT>to<FONT style="font-size:8.7pt"> &nbsp;&nbsp;</FONT>cancer<FONT style="font-size:8.65pt"> &nbsp;&nbsp;</FONT>cells<FONT style="font-size:8.65pt"> &nbsp;&nbsp;</FONT>(<font style='font-family:Arial Unicode MS,Times New Roman'>&#8216;</font>stealth<font style='font-family:Arial Unicode MS,Times New Roman'>&#8217;</font><FONT style="font-size:8.65pt"> &nbsp;&nbsp;</FONT>technology).<FONT style="font-size:8.75pt"> &nbsp;&nbsp;</FONT>CS-6<FONT style="font-size:8.8pt"> &nbsp;&nbsp;</FONT>shows<FONT style="font-size:8.85pt"> &nbsp;&nbsp;</FONT>broad<FONT style="font-size:8.6pt"> &nbsp;&nbsp;</FONT>anti-</P>
<P style="margin-top:4.933px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">proliferative<FONT style="font-size:10.35pt"> &nbsp;</FONT>and<FONT style="font-size:10.2pt"> &nbsp;</FONT>cytotoxic<FONT style="font-size:10.35pt"> &nbsp;</FONT>activity<FONT style="font-size:10.25pt"> &nbsp;</FONT>against<FONT style="font-size:10.35pt"> &nbsp;</FONT>human<FONT style="font-size:10.35pt"> &nbsp;</FONT>cancer<FONT style="font-size:10.25pt"> &nbsp;</FONT>cells,<FONT style="font-size:10.4pt"> &nbsp;</FONT>with<FONT style="font-size:10pt"> &nbsp;</FONT>particular</P>
<P style="margin-top:5.133px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">activity<FONT style="font-size:10pt"> &nbsp;&nbsp;&nbsp;</FONT>against<FONT style="font-size:10.1pt"> &nbsp;&nbsp;&nbsp;</FONT>human<FONT style="font-size:10.1pt"> &nbsp;&nbsp;&nbsp;</FONT>glioblastoma<FONT style="font-size:10.05pt"> &nbsp;&nbsp;&nbsp;</FONT>cells.<FONT style="font-size:10.1pt"> &nbsp;&nbsp;&nbsp;</FONT>CS-6<FONT style="font-size:10pt"> &nbsp;&nbsp;&nbsp;</FONT>also<FONT style="font-size:10.2pt"> &nbsp;&nbsp;&nbsp;</FONT>has<FONT style="font-size:10.05pt"> &nbsp;&nbsp;&nbsp;</FONT>been<FONT style="font-size:10.1pt"> &nbsp;&nbsp;&nbsp;</FONT>designed</P>
<P style="margin-top:4.933px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">deliberately<FONT style="font-size:9.3pt"> &nbsp;&nbsp;</FONT>to<FONT style="font-size:9.45pt"> &nbsp;&nbsp;</FONT>meet<FONT style="font-size:9.45pt"> &nbsp;&nbsp;</FONT>the<FONT style="font-size:9.4pt"> &nbsp;&nbsp;</FONT>major<FONT style="font-size:9.3pt"> &nbsp;&nbsp;</FONT>known<FONT style="font-size:9.4pt"> &nbsp;&nbsp;</FONT>criteria<FONT style="font-size:9.45pt"> &nbsp;&nbsp;</FONT>for<FONT style="font-size:9.3pt"> &nbsp;&nbsp;</FONT>crossing<FONT style="font-size:9.35pt"> &nbsp;&nbsp;</FONT>the<FONT style="font-size:9.45pt"> &nbsp;&nbsp;</FONT>blood-brain</P>
<P style="margin-top:4.933px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">barrier,<FONT style="font-size:6.9pt"> &nbsp;</FONT>and<FONT style="font-size:6.65pt"> &nbsp;</FONT>for<FONT style="font-size:6.65pt"> &nbsp;</FONT>that<FONT style="font-size:6.85pt"> &nbsp;</FONT>reason<FONT style="font-size:6.8pt"> &nbsp;</FONT>is<FONT style="font-size:6.8pt"> &nbsp;</FONT>being<FONT style="font-size:6.7pt"> &nbsp;</FONT>developed<FONT style="font-size:6.65pt"> &nbsp;</FONT>as<FONT style="font-size:6.8pt"> &nbsp;</FONT>a<FONT style="font-size:6.8pt"> &nbsp;</FONT>first-line<FONT style="font-size:6.9pt"> &nbsp;</FONT>for<FONT style="font-size:6.65pt"> &nbsp;</FONT>the<FONT style="font-size:6.8pt"> &nbsp;</FONT>treatment<FONT style="font-size:6.85pt"> &nbsp;</FONT>of</P>
<P style="margin-top:4.933px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">glioblastoma multiforme, the main form of primary brain cancer.</P>
<P style="margin-top:27.867px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt"><B>Further information</B></P>
<P style="margin-top:4.933px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">Contact Dr Graham Kelly, Chief Executive Officer.</P>
<P style="margin-top:27.867px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">T: &nbsp;(61 2) 9878 0088</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">M: (61) 0459 200 095</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">E: Graham.Kelly@novogen.com</P>
<P style="margin-top:23.867px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">Further information is available on the Company<font style='font-family:Arial Unicode MS,Times New Roman'>&#8217;</font>s web site, www.novogen.com</P>
<P style="margin-top:23.867px; margin-bottom:0px"><BR>
<BR></P>
</DIV></BODY>
<!-- EDGAR Validation Code: 6A80C525 -->
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
